Neuroscientific Biopharmaceuticals Ltd. (AU:NSB)
ASX:NSB
Want to see AU:NSB full AI Analyst Report?
NSB Stock Chart & Stats
AU$0.10
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.10
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.26
Previous CloseN/A
Volume70.60K
Average Volume (3M)306.60K
Market Cap
AU$36.24M
Enterprise ValueAU$29.49M
Total Cash (Recent Filing)AU$7.27M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding389,718,540
10 Day Avg. Volume291,172
30 Day Avg. Volume306,603
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.76
Price to Sales (P/S)0.00
P/FCF Ratio-13.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially reduces solvency and interest-cost risk for a capital-intensive biotech. Over 2–6 months this improves financial flexibility for timing financings, lowers default risk, and preserves optionality to pursue clinical programs without immediate debt servicing pressures.
Lean Operating StructureA very small headcount implies a lean cost base and operational agility. For an R&D-focused biotech, a compact team can stretch limited cash, reduce fixed overhead, and enable focused program execution, helping preserve runway between financing rounds.
Intermittent Positive Cash GenerationA modest positive operating/free cash flow year demonstrated the company can occasionally align spending and receipts. This suggests some operational discipline and the potential to manage cash outflows, which helps extend runway and reduces immediate fundraising frequency risk.
Bears Say
Revenue CollapseA fall to zero reported revenue eliminates self-funding capacity and signals weak commercial traction or discontinued revenue streams. Over several months this severely limits internal financing options, heightens dependence on external capital, and raises execution risk for development plans.
Sustained Operating LossesPersistent operating deficits indicate the company cannot currently generate profits from its activities. Continued losses erode equity, strain cash reserves, and typically require serial financings that dilute shareholders and constrain long-term investment choices.
Ongoing Cash BurnChronic negative cash flow and a sharp 2025 deterioration increase funding urgency. Over 2–6 months this raises the probability of dilutive financings or program cutbacks, undermining continuity of R&D projects and increasing execution and regulatory-timeline risk.
Neuroscientific Biopharmaceuticals Ltd. News
NSB FAQ
What was Neuroscientific Biopharmaceuticals Ltd.’s price range in the past 12 months?
Neuroscientific Biopharmaceuticals Ltd. lowest share price was AU$0.05 and its highest was AU$0.26 in the past 12 months.
What is Neuroscientific Biopharmaceuticals Ltd.’s market cap?
Neuroscientific Biopharmaceuticals Ltd.’s market cap is AU$36.24M.
When is Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date?
Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 83 days.
How were Neuroscientific Biopharmaceuticals Ltd.’s earnings last quarter?
Neuroscientific Biopharmaceuticals Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Neuroscientific Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Neuroscientific Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Neuroscientific Biopharmaceuticals Ltd. pay dividends?
Neuroscientific Biopharmaceuticals Ltd. does not currently pay dividends.
What is Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate?
Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neuroscientific Biopharmaceuticals Ltd. have?
Neuroscientific Biopharmaceuticals Ltd. has 389,718,540 shares outstanding.
What happened to Neuroscientific Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Neuroscientific Biopharmaceuticals Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Neuroscientific Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:NSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuroscientific Biopharmaceuticals Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:NSB Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
265.85%
12-Months-Change
Fundamentals
Return on Equity
-19.10%
Trailing 12-Months
Asset Growth
232.64%
Trailing 12-Months
Company Description
Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
Island Pharmaceuticals Ltd
―
AnteoTech Ltd
―
Options Prices
Currently, No data available
---